34625112|t|Activation of PLCbeta1 enhances endocannabinoid mobilization to restore hippocampal spike-timing-dependent potentiation and contextual fear memory impaired by Alzheimer's amyloidosis.
34625112|a|BACKGROUND: Accumulation of amyloid beta oligomers (AbetaO) in Alzheimer's disease (AD) impairs hippocampal long-term potentiation (LTP), leading to memory deficits. Thus, identifying the molecular targets of AbetaO involved in LTP inhibition is critical for developing therapeutics for AD. Endocannabinoid (eCB) synthesis and release, a process collectively called eCB mobilization by hippocampal CA1 pyramidal cells, is known to facilitate LTP induction. eCB can be mobilized either by postsynaptic depolarization in an intracellular Ca2+ concentration ([Ca2+]i)-dependent pathway or by group 1 metabotropic glutamate receptor (mGluR) activation in a phospholipase Cbeta (PLCbeta)-dependent pathway. Moreover, group 1 mGluR activation during postsynaptic depolarization, which is likely to occur in vivo during memory processing, can cause synergistic enhancement of eCB (S-eCB) mobilization in a PLCbeta-dependent pathway. Although AbetaO has been shown to disrupt [Ca2+]i-dependent eCB mobilization, the effect of AbetaO on PLCbeta-dependent S-eCB mobilization and its association with LTP and hippocampus-dependent memory impairments in AD is unknown. METHODS: We used in vitro whole-cell patch-clamp recordings and western blot analyses to investigate the effect of AbetaO on PLCbeta protein levels, PLCbeta-dependent S-eCB mobilization, and spike-timing-dependent potentiation (tLTP) in AbetaO-treated rat hippocampal slices in vitro. In addition, we assessed the relationship between PLCbeta protein levels and hippocampus-dependent memory impairment by performing a contextual fear memory task in vivo in the 5XFAD mouse model of AD. RESULTS: We found that AbetaO treatment in rat hippocampal slices in vitro decreased hippocampal PLCbeta1 protein levels and disrupted S-eCB mobilization, as measured by western blot analysis and in vitro whole-cell patch-clamp recordings. This consequently led to the impairment of NMDA receptor (NMDAR)-mediated tLTP at CA3-CA1 excitatory synapses in AbetaO-treated rat hippocampal slices in vitro. Application of the PLCbeta activator, m-3M3FBS, in rat hippocampal slices reinstated PLCbeta1 protein levels to fully restore S-eCB mobilization and NMDAR-mediated tLTP. In addition, direct hippocampal injection of m-3M3FBS in 5XFAD mice reinstated PLCbeta1 protein levels to those observed in wild type control mice and fully restored hippocampus-dependent contextual fear memory in vivo in 5XFAD mice. CONCLUSION: We suggest that these results might be the consequence of memory impairment in AD by disrupting S-eCB mobilization. Therefore, we propose that PLCbeta-dependent S-eCB mobilization could provide a new therapeutic strategy for treating memory deficits in AD.
34625112	14	22	PLCbeta1	Gene	24654
34625112	32	47	endocannabinoid	Chemical	MESH:D063388
34625112	140	155	memory impaired	Disease	MESH:D008569
34625112	159	182	Alzheimer's amyloidosis	Disease	MESH:D000544
34625112	236	242	AbetaO	Gene	80908
34625112	247	266	Alzheimer's disease	Disease	MESH:D000544
34625112	268	270	AD	Disease	MESH:D000544
34625112	333	348	memory deficits	Disease	MESH:D008569
34625112	393	399	AbetaO	Gene	80908
34625112	471	473	AD	Disease	MESH:D000544
34625112	475	490	Endocannabinoid	Chemical	MESH:D063388
34625112	492	495	eCB	Chemical	MESH:D063388
34625112	550	553	eCB	Chemical	MESH:D063388
34625112	641	644	eCB	Chemical	MESH:D063388
34625112	720	724	Ca2+	Chemical	-
34625112	741	745	Ca2+	Chemical	-
34625112	814	819	mGluR	Gene	60590
34625112	1053	1056	eCB	Chemical	MESH:D063388
34625112	1058	1063	S-eCB	Chemical	MESH:D063388
34625112	1119	1125	AbetaO	Gene	80908
34625112	1153	1157	Ca2+	Chemical	-
34625112	1170	1173	eCB	Chemical	MESH:D063388
34625112	1202	1208	AbetaO	Gene	80908
34625112	1230	1235	S-eCB	Chemical	MESH:D063388
34625112	1304	1322	memory impairments	Disease	MESH:D008569
34625112	1326	1328	AD	Disease	MESH:D000544
34625112	1456	1462	AbetaO	Gene	100301568
34625112	1508	1513	S-eCB	Chemical	MESH:D063388
34625112	1578	1584	AbetaO	Gene	100301568
34625112	1593	1596	rat	Species	10116
34625112	1725	1742	memory impairment	Disease	MESH:D008569
34625112	1808	1813	mouse	Species	10090
34625112	1823	1825	AD	Disease	MESH:D000544
34625112	1850	1856	AbetaO	Gene	100301568
34625112	1870	1873	rat	Species	10116
34625112	1924	1932	PLCbeta1	Gene	24654
34625112	1962	1967	S-eCB	Chemical	MESH:D063388
34625112	2180	2186	AbetaO	Gene	100301568
34625112	2195	2198	rat	Species	10116
34625112	2266	2274	m-3M3FBS	Chemical	MESH:C473783
34625112	2279	2282	rat	Species	10116
34625112	2313	2321	PLCbeta1	Gene	24654
34625112	2354	2359	S-eCB	Chemical	MESH:D063388
34625112	2443	2451	m-3M3FBS	Chemical	MESH:C473783
34625112	2461	2465	mice	Species	10090
34625112	2477	2485	PLCbeta1	Gene	24654
34625112	2540	2544	mice	Species	10090
34625112	2626	2630	mice	Species	10090
34625112	2702	2719	memory impairment	Disease	MESH:D008569
34625112	2723	2725	AD	Disease	MESH:D000544
34625112	2740	2745	S-eCB	Chemical	MESH:D063388
34625112	2805	2810	S-eCB	Chemical	MESH:D063388
34625112	2878	2893	memory deficits	Disease	MESH:D008569
34625112	2897	2899	AD	Disease	MESH:D000544
34625112	Negative_Correlation	100301568	24654
34625112	Association	MESH:D063388	MESH:D008569
34625112	Association	MESH:D000544	24654
34625112	Association	MESH:D063388	80908
34625112	Association	MESH:D008569	24654
34625112	Association	MESH:D000544	80908
34625112	Association	MESH:D063388	24654
34625112	Positive_Correlation	MESH:D008569	80908
34625112	Positive_Correlation	MESH:C473783	24654
34625112	Association	MESH:D063388	MESH:D000544

